Snigdha Vallabhaneni1,2, Nicky Longley3,4, Mariette Smith5, Rachel Smith2, Meg Osler5, Nicola Kelly4, Anna Cross4, Andrew Boulle5,6,7, Graeme Meintjes7, Nelesh P Govender8. 1. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2. Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. St. George's, University of London, London, UK. 4. Desmond Tutu HIV/AIDS Foundation, University of Cape Town, Cape Town, South Africa. 5. Centre for Infectious Diseases, Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 6. Department of Health, Provincial Government of the Western Cape, Cape Town, South Africa. 7. Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town. 8. National Institute for Communicable Diseases - Centre for Opportunistic, Tropical and Hospital Infections, a Division of the National Health Laboratory Service, Johannesburg, South Africa and Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Abstract
BACKGROUND: Screening for serum cryptococcal antigen (CrAg) may identify those at risk for disseminated cryptococcal disease (DCD), and preemptive fluconazole treatment may prevent progression to DCD. In August 2012, the Western Cape Province (WC), South Africa, adopted provider-initiated CrAg screening. We evaluated the implementation and effectiveness of this large-scale public-sector program during its first year, September 1, 2012-August 31, 2013. METHODS: We used data from the South African National Health Laboratory Service, WC provincial HIV program, and nationwide surveillance data for DCD. We assessed the proportion of eligible patients screened for CrAg (CrAg test done within 30 days of CD4 date) and the prevalence of CrAg positivity. Incidence of DCD among those screened was compared with those not screened. RESULTS: Of 4395 eligible patients, 26.6% (n = 1170) were screened. The proportion of patients screened increased from 15.9% in September 2012 to 36.6% in August 2013. The prevalence of positive serum CrAg was 2.1%. Treatment data were available for 13 of 24 CrAg-positive patients; 9 of 13 were treated with fluconazole. Nine (0.8%) incident cases of DCD occurred among the 1170 patients who were screened for CrAg vs. 49 (1.5%) incident cases among the 3225 patients not screened (P = 0.07). CONCLUSIONS: Relatively few eligible patients were screened under the WC provider-initiated CrAg screening program. Unscreened patients were nearly twice as likely to develop DCD. CrAg screening can reduce the burden of DCD, but needs to be implemented well. To improve screening rates, countries should consider laboratory-based reflexive screening when possible.
BACKGROUND: Screening for serum cryptococcal antigen (CrAg) may identify those at risk for disseminated cryptococcal disease (DCD), and preemptive fluconazole treatment may prevent progression to DCD. In August 2012, the Western Cape Province (WC), South Africa, adopted provider-initiated CrAg screening. We evaluated the implementation and effectiveness of this large-scale public-sector program during its first year, September 1, 2012-August 31, 2013. METHODS: We used data from the South African National Health Laboratory Service, WC provincial HIV program, and nationwide surveillance data for DCD. We assessed the proportion of eligible patients screened for CrAg (CrAg test done within 30 days of CD4 date) and the prevalence of CrAg positivity. Incidence of DCD among those screened was compared with those not screened. RESULTS: Of 4395 eligible patients, 26.6% (n = 1170) were screened. The proportion of patients screened increased from 15.9% in September 2012 to 36.6% in August 2013. The prevalence of positive serum CrAg was 2.1%. Treatment data were available for 13 of 24 CrAg-positive patients; 9 of 13 were treated with fluconazole. Nine (0.8%) incident cases of DCD occurred among the 1170 patients who were screened for CrAg vs. 49 (1.5%) incident cases among the 3225 patients not screened (P = 0.07). CONCLUSIONS: Relatively few eligible patients were screened under the WC provider-initiated CrAg screening program. Unscreened patients were nearly twice as likely to develop DCD. CrAg screening can reduce the burden of DCD, but needs to be implemented well. To improve screening rates, countries should consider laboratory-based reflexive screening when possible.
Authors: Joseph N Jarvis; Thomas S Harrison; Nelesh Govender; Stephen D Lawn; Nicky Longley; Tihana Bicanic; Gary Maartens; Francois Venter; Linda-Gail Bekker; Robin Wood; Graeme Meintjes Journal: S Afr Med J Date: 2011-04
Authors: Sayoki Mfinanga; Duncan Chanda; Sokoine L Kivuyo; Lorna Guinness; Christian Bottomley; Victoria Simms; Carol Chijoka; Ayubu Masasi; Godfather Kimaro; Bernard Ngowi; Amos Kahwa; Peter Mwaba; Thomas S Harrison; Saidi Egwaga; Shabbar Jaffar Journal: Lancet Date: 2015-03-10 Impact factor: 79.321
Authors: Stephen D Lawn; Francesca Little; Linda-Gail Bekker; Richard Kaplan; Elizabeth Campbel; Catherine Orrell; Robin Wood Journal: AIDS Date: 2009-01-28 Impact factor: 4.177
Authors: Mark D Lindsley; Nanthawan Mekha; Henry C Baggett; Yupha Surinthong; Rinrapas Autthateinchai; Pongpun Sawatwong; Julie R Harris; Benjamin J Park; Tom Chiller; S Arunmozhi Balajee; Natteewan Poonwan Journal: Clin Infect Dis Date: 2011-08 Impact factor: 9.079
Authors: Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison Journal: Clin Infect Dis Date: 2013-12-06 Impact factor: 9.079
Authors: Meg Osler; Katherine Hilderbrand; Claudine Hennessey; Juanita Arendse; Eric Goemaere; Nathan Ford; Andrew Boulle Journal: J Int AIDS Soc Date: 2014-04-28 Impact factor: 5.396
Authors: Elizabeth Nalintya; David B Meya; Sarah Lofgren; Kathy Huppler Hullsiek; David R Boulware; Radha Rajasingham Journal: J Acquir Immune Defic Syndr Date: 2018-06-01 Impact factor: 3.731
Authors: William J Hurt; Mark W Tenforde; Mooketsi Molefi; Hannah K Mitchell; Thandi Milton; Martin S Azama; Irene Goercke; Fredah Mulenga; Nametso Tlhako; Katlego Tsholo; Tuhina Srivastava; Tshepo B Leeme; Godfrey Simoonga; Charles Muthoga; Kwana Lechiile; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2021-05-18 Impact factor: 9.079
Authors: Sisanda Gaga; Nokuzola Mqoqi; Raymond Chimatira; Singilizwe Moko; Jude O Igumbor Journal: South Afr J HIV Med Date: 2021-05-12 Impact factor: 2.744
Authors: Nathan Ford; Zara Shubber; Joseph N Jarvis; Tom Chiller; Greg Greene; Chantal Migone; Marco Vitoria; Meg Doherty; Graeme Meintjes Journal: Clin Infect Dis Date: 2018-03-04 Impact factor: 9.079
Authors: Sarah M Lofgren; Elizabeth Nalintya; David B Meya; David R Boulware; Radha Rajasingham Journal: Medicine (Baltimore) Date: 2018-08 Impact factor: 1.817